PreprintThis is the submitted version of a paper published in Naunyn-Schmiedeberg's Archives of Pharmacology.
Citation for the original published paper (version of record):Webb, D-L., Rudholm-Feldreich, T., Gillberg, L., Halim, A., Theodorsson, E. et al. (2013) The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression. Pharmacology, http://dx.doi.org/10.1007/s00210-012-0812-5
Naunyn-Schmiedeberg's Archives ofAccess to the published version may require subscription. N.B. When citing this work, cite the original published paper.
Permanent link to this version:http://urn.kb. se/resolve?urn=urn:nbn:se:uu:diva-193524 Naunyn-Schmiedeberg's Archives of PharmacologyThe type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 Conclusions: YF476 is a potential new preventative treatment for patients at risk of NSAIDinduced ulceration. Gastric gene expressions of ghrelin, gastrin and somatostatin and their receptors differ between esomeprazole and YF476. Despite these differences and different modes of action to raise gastric pH, both drugs acutely increase iNOS, suggesting iNOS expression parallels pH.